Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
about
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsA perspective on the structure and receptor binding properties of immunoglobulin G FcTargeting the Fc receptor in autoimmune diseaseUnraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based TherapeuticsAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeTargeting FcRn for the modulation of antibody dynamicsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyModern Technologies for Creating Synthetic Antibodies for Clinical application.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptorTargeting FcRn for therapy: from live cell imaging to in vivo studies in mice.Engineered clearing agents for the selective depletion of antigen-specific antibodiesClinical ramifications of the MHC family Fc receptor FcRn.Characterization and screening of IgG binding to the neonatal Fc receptor.Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.Polymeric human Fc-fusion proteins with modified effector functions.Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-lifeA novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.The immunologic functions of the neonatal Fc receptor for IgGAn engineered selenocysteine defines a unique class of antibody derivatives.Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice.Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.Inhibitors of the FcRn:IgG protein-protein interaction.Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsDevelopmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.Commentary: "There's been a Flaw in Our Thinking".Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
P2860
Q26822421-24B2B14A-30CE-4A79-9880-F3BC2B678AB4Q26827579-01C449EE-4A91-4C93-A377-1DF37B5D480CQ27002843-66AD3138-C8F5-4C90-999D-8BEBBABD6515Q27027238-6BD74A2B-637A-467A-B530-18788BF4274AQ28079016-59021AB2-FDC6-439B-8264-BD70F4005E9CQ28080589-DBCFBFA2-2B3B-4D94-B88E-E151FDE68653Q28257521-59D7ECC1-262B-4DC6-AFDA-872925EBBA2AQ30467308-0B33FF21-EAB2-42D5-B15F-07FB5086815DQ30566003-49AD341F-43B9-4E7A-9EDF-C8A00C3F1631Q33573587-7D7127B4-E41A-4817-907D-78CCA61BF7C7Q33758483-F4EB6B63-FE62-4F15-8CD5-441E224DB1E2Q33766669-D9C49B03-EA8E-490C-9C0B-2A90D8B562DFQ34754673-D142804E-B367-459A-AB54-E35007902680Q35163945-64BC6B71-3062-4220-9257-05C1FCED682BQ35170050-6FEA33FE-2867-44EB-B1B7-FE00BD771418Q35551564-0ACDAEBE-394D-41A0-853A-D8AB2D3178CEQ35899107-F1CD929A-117F-4290-B08D-9DEF956D5DECQ36080399-DD57D933-FB34-4B79-92AE-D42BDDF627ABQ36211427-F87B006B-2E48-4E46-85FB-46A1CD9E3106Q36542347-30A98DD0-4D11-4D34-9DB9-DBF1248CC0D8Q36843553-031784CF-EB6E-4745-AADB-ECB0DE263617Q37115251-D39C58A2-F131-4B3B-89A9-5375105E093AQ37334251-1E4F9D3A-47D2-4CF3-BDD3-9730119F1FC3Q37364343-95403227-7835-4EEE-BDE7-E8868D28E15FQ37508794-2DCDC80F-32E9-4921-BEF7-70893E0DCC36Q37597698-2A4974AB-6861-43BD-A25F-80B6D7DD90E5Q37698914-B05F84FE-D381-4CD6-AD50-591D524A64D7Q37798387-44B7928D-9015-4A4A-83CB-5A79A268BD21Q37986126-FF0F23B4-4E31-4A39-94D2-B80A65D817EEQ37998314-B5368B0C-71B5-423D-9C77-68BB3A3EACD8Q38718049-D8213B2F-30A8-471A-8C60-F213EFD3946FQ38821056-7FC0DF59-8665-48A0-8718-3827E69FDDADQ38883267-F0DFDC42-7C06-4098-9BB3-489B4E625AD8Q39388182-5476635F-AE62-498D-B835-9E983B44F085Q39540318-C8FE2143-E606-4581-AAAB-8F91268D291AQ39959699-1663DF2F-CA61-4C8E-81B6-C1A21C790D33Q41704150-DA682A76-EFCF-4C4E-871F-334074F77D68Q41931879-DE197DBD-BB66-4337-B3DD-75A62EE7AAD3Q42173120-C3C67AAE-5221-437B-BA86-85E765E0D504Q42557601-4CA05466-8F28-417B-B991-2962B9987A3A
P2860
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Divergent activities of an eng ...... ns for therapeutic antibodies.
@ast
Divergent activities of an eng ...... ns for therapeutic antibodies.
@en
type
label
Divergent activities of an eng ...... ns for therapeutic antibodies.
@ast
Divergent activities of an eng ...... ns for therapeutic antibodies.
@en
prefLabel
Divergent activities of an eng ...... ns for therapeutic antibodies.
@ast
Divergent activities of an eng ...... ns for therapeutic antibodies.
@en
P2093
P2860
P356
P1476
Divergent activities of an eng ...... ns for therapeutic antibodies.
@en
P2093
Carlos Vaccaro
E Sally Ward
Raimund J Ober
Roger Bawdon
Sylvia Wanjie
P2860
P304
18709-18714
P356
10.1073/PNAS.0606304103
P407
P577
2006-11-20T00:00:00Z